论文部分内容阅读
目的:探讨莫西沙星溶液雾化吸入对于慢性阻塞性肺疾病(COPD)并发呼吸衰竭的临床治疗效果。方法:将100例慢性阻塞性肺疾病并发呼吸衰竭患者随机分成治疗组和对照组,每组50例。对照组采用沙丁胺醇雾化吸入治疗,治疗组采用莫西沙星溶液雾化吸入治疗。对两组治疗前后主观症状、临床疗效、肺功能改善情况及不良反应进行比较。结果:治疗后,两组主观症状量表得分显著降低,治疗组主观症状量表得分为(1.2±0.7),显著低于对照组的(2.7±1.0),差异有统计学意义(P<0.05);治疗组治疗有效率为94.0%,显著高于对照组的68.0%,差异有统计学意义(P<0.05);治疗后,两组PaO2显著升高,治疗组PaO2为(9.87±1.89)kPa,显著高于对照组的(9.75±1.54)kPa,差异有统计学意义(P<0.05);两组PaCO2显著降低,治疗组PaCO2为(5.44±0.45)kPa,显著低于对照组的(5.49±0.90)kPa,差异有统计学意义(P<0.05);治疗后两组患者的肺功能均显著提高,治疗组患者FEV1、FEV1/FCV、6-MWD均显著性优于对照组,差异有统计学意义(P<0.05);两组治疗中均未出现严重不良反应。结论:莫西沙星溶液雾化吸入可以有效治疗COPD并发呼吸衰竭。
Objective: To investigate the clinical effect of moxifloxacin aerosol inhalation on chronic obstructive pulmonary disease (COPD) complicated with respiratory failure. Methods: 100 patients with chronic obstructive pulmonary disease complicated by respiratory failure were randomly divided into treatment group and control group, 50 cases in each group. The control group was treated with inhalation of salbutamol inhalation, the treatment group was treated with moxifloxacin nebulized inhalation. The subjective symptoms, clinical efficacy, improvement of pulmonary function and adverse reactions in both groups were compared before and after treatment. Results: After treatment, scores of subjective symptom scores decreased significantly in the two groups, and scores of subjective symptom scores in the treatment group were (1.2 ± 0.7), which were significantly lower than those in the control group (2.7 ± 1.0) (P <0.05 ). The effective rate of the treatment group was 94.0%, significantly higher than that of the control group (68.0%), the difference was statistically significant (P <0.05); After treatment, PaO2 was significantly increased in both groups, PaO2 was (9.87 ± 1.89) kPa, which was significantly higher than that of the control group (9.75 ± 1.54 kPa) (P <0.05). PaCO2 in the two groups was significantly lower than that in the control group (5.44 ± 0.45 kPa), which was significantly lower than that in the control group 5.49 ± 0.90) kPa, the difference was statistically significant (P <0.05). After treatment, lung function of both groups was significantly improved. The FEV1, FEV1 / FCV and 6-MWD in the treatment group were significantly better than those in the control group There was statistical significance (P <0.05). No serious adverse reactions occurred in both groups. Conclusion: Moxifloxacin solution inhalation can effectively treat COPD complicated by respiratory failure.